BBOT (BridgeBio Oncology Therapeutics) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
| Website | https://www.bbotx.com |
| Employees | 103 (76 on RocketReach) |
| Address | 256 E Grand Ave Suite 104, South San Francisco, California 94080, US |
| Industry | Biotechnology Research |
Looking for a particular BBOT employee's phone or email?
Eli Wallace is the CEO of BBOT.
76 people are employed at BBOT.
BBOT is based in South San Francisco, California.